Overview

Safety and Efficacy of HB-1 for Panic Disorder

Status:
Not yet recruiting

Trial end date:
2022-10-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of HB-1 versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with Panic Disorder.

Phase:

Phase 2

Details

Lead Sponsor:

Honeybrains Biotech LLC

Collaborator:

Cognitive Research Corporation